Aron Jansen

Aron Jansen

Auto-generated profile, based on publicly available information

Aron Jansen

Radboud university medical center, Radboud Institute for Molecular Life Sciences, Department of Intensive Care Medicine, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands; Radboud Center for Infectious Diseases (RCI), Radboud university medical center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
DSDavid P. Schrijver
David P. Schrijver
RRRutger J. Röring
Rutger J. Röring
JDJeroen Deckers
Jeroen Deckers
ADAnne de Dreu
Anne de Dreu
YTYohana C. Toner
Yohana C. Toner
WMWillem J. M. Mulder
Willem J. M. Mulder
Immunoparalysis is a compensatory and persistent anti-inflammatory response to trauma, sepsis or another serious insult, which increases the risk of opportunistic infections, morbidity and mortality. Here, we show that in cultured primary human monocytes, interleukin-4 (IL4) inhibits acute inflammation, while simultaneously inducing a long-lasting innate immune memory named trained immunity. To take advantage of this paradoxical IL4 feature in vivo, we developed a fusion protein of apolipoprotein A1 (apoA1) and IL4, which integrates into a lipid nanoparticle. In mice and non-human primates, an intravenously injected apoA1-IL4-embedding nanoparticle targets myeloid-cell-rich haematopoietic organs, in particular, the spleen and bone marrow. We subsequently demonstrate that IL4 nanotherapy resolved immunoparalysis in mice with lipopolysaccharide-induced hyperinflammation, as well as in ex vivo human sepsis models and in experimental endotoxemia. Our findings support the translational development of nanoparticle formulations of apoA1-IL4 for the treatment of patients with sepsis at risk of immunoparalysis-induced complications.

21 March 2023 in Critical Care
Verified
Journal Article
Open access
PDF file
AJAron Jansen
Aron Jansen
NWNicole J. B. Waalders
Nicole J. B. Waalders
DLDirk P. T. van Lier
Dirk P. T. van Lier
MKMatthijs Kox
Matthijs Kox
PPPeter Pickkers
Peter Pickkers
Background: The CytoSorb hemoadsorption device has been demonstrated to be capable of clearing inflammatory cytokines, but has not yet been shown to attenuate plasma cytokine concentrations. We investigated the effects of CytoSorb hemoperfusion on plasma levels of various cytokines using the repeated human experimental endotoxemia model, a highly standardized and reproducible human in vivo model of systemic inflammation and immunological tolerance induced by administration of bacterial lipopolysaccharide (LPS). Methods: Twenty-four healthy male volunteers (age 18–35) were intravenously challenged with LPS (a bolus of 1 ng/kg followed by continuous infusion of 0.5 ng/kg/hr for three hours) twice: on day 0 to quantify the initial cytokine response and on day 7 to quantify the degree of endotoxin tolerance. Subjects either received CytoSorb hemoperfusion during the first LPS challenge (CytoSorb group), or no intervention (control group). Plasma cytokine concentrations and clearance rates were determined serially. This study was registered at ClinicalTrials.gov (NCT04643639, date of registration November 24th 2020). Results: LPS administration led to a profound increase in plasma cytokine concentrations during both LPS challenge days. Compared to the control group, significantly lower plasma levels of tumor necrosis factor (TNF, − 58%, p < 0.0001), interleukin (IL)-6 ( − 71%, p = 0.003), IL-8 ( − 48%, p = 0.02) and IL-10 ( − 26%, p = 0.03) were observed in the CytoSorb group during the first LPS challenge. No differences in cytokine responses were observed during the second LPS challenge. Conclusions: CytoSorb hemoperfusion effectively attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo, whereas it does not affect long-term immune function. Therefore, CytoSorb therapy may be of benefit in conditions characterized by excessive cytokine release.

8 August 2022 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
AJAron Jansen
Aron Jansen
NBNiklas Bruse
Niklas Bruse
NWNicole Waalders
Nicole Waalders
JGJelle Gerretsen
Jelle Gerretsen
DRDaniëlle Rijbroek
Daniëlle Rijbroek
MKMatthijs Kox
Matthijs Kox
Cytokine production by ex vivo (EV)-stimulated leukocytes is commonly used to gauge immune function and frequently proposed to guide immunomodulatory therapy. However, whether EV cytokine production capacity accurately reflects the in vivo (IV) immune status is largely unknown. We investigated relationships between EV monocyte cytokine responses and IV cytokine responses in a large cohort of healthy volunteers using a highly standardized IV model of short-lived LPS-induced systemic inflammation, which captures hallmarks of both hyperinflammation and immunological tolerance. Therefore, 110 healthy volunteers were intravenously challenged with 1 ng/kg LPS twice: on day 0 to determine the extent of the IV (hyper)inflammatory response and on day 7 to determine the degree of IV endotoxin tolerance. Baseline EV monocyte cytokine production capacity was assessed prior to LPS administration. Short-term and long-term EV tolerance was assessed in monocytes isolated 4 h and 7 days after LPS administration, respectively. No robust correlations were observed between baseline EV cytokine production capacity and IV cytokine responses following LPS administration. However, highly robust inverse correlations were observed between IV cytokine responses and EV cytokine responses of monocytes isolated 4 h after IV LPS administration. No correlations between IV and EV tolerance were found. In conclusion, attenuated EV cytokine production capacity reflects ongoing IV inflammation rather than immune suppression. Results of EV assays should be interpreted with caution at the risk of improper use of immuno­stimulatory drugs.

29 May 2023 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
BLB.I.H.M. Lambregts
B.I.H.M. Lambregts
EVE. Vassena
E. Vassena
AJA. Jansen
A. Jansen
DSD.E. Stremmelaar
D.E. Stremmelaar
PPP. Pickkers
P. Pickkers
MSM.E. van der Schaaf
M.E. van der Schaaf
Earlier work within the physical domain showed that acute inflammation changes motivational prioritization and effort allocation rather than physical abilities. It is currently unclear whether a similar motivational framework accounts for the mental fatigue and cognitive symptoms of acute sickness. Accordingly, this study aimed to assess the relationship between fatigue, cytokines and mental effort-based decision making during acute systemic inflammation. Eighty-five participants (41 males; 18-30 years (M = 23.0, SD = 2.4)) performed a mental effort-based decision-making task before, 2 h after, and 5 h after intravenous administration of 1 ng/kg bacterial lipopolysaccharide (LPS) to induce systemic inflammation. Plasma concentrations of cytokines (interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)) and fatigue levels were assessed at similar timepoints. In the task, participants decided whether they wanted to perform (i.e., 'accepted') arithmetic calculations of varying difficulty (3 levels: easy, medium, hard) in order to obtain rewards (3 levels: 5, 6 or 7 points). Acceptance rates were analyzed using a binomial generalized estimated equation (GEE) approach with effort, reward and time as independent variables. Arithmetic performance was measured per effort level prior to the decisions and included as a covariate. Associations between acceptance rates, fatigue (self-reported) and cytokine concentration levels were analyzed using partial correlation analyses. Plasma cytokine concentrations and fatigue were increased at 2 h post-LPS compared to baseline and 5 h post-LPS administration. Acceptance rates decreased for medium, but not for easy or hard effort levels at 2 h post-LPS versus baseline and 5 h post-LPS administration, irrespective of reward level. These reductions in acceptance rates occurred despite improved accuracy on the arithmetic calculations itself. Reduced acceptance rates for medium effort were associated with increased fatigue, but not with increased cytokine concentrations. Fatigue during acute systemic inflammation is associated with alterations in mental effort allocation, similarly as observed previously for physical effort-based choice. Specifically, willingness to exert mental effort depended on effort and not reward information, while task accuracy was preserved. These results extend the motivational account of inflammation to the mental domain and suggest that inflammation may not necessarily affect domain-specific mental abilities, but rather affects domain-general effort-allocation processes.

20 June 2023 in Microbes and Infection
Verified
Journal Article
Open access
NBNiklas Bruse
Niklas Bruse
AJAron Jansen
Aron Jansen
JGJelle Gerretsen
Jelle Gerretsen
DRDanielle Rijbroek
Danielle Rijbroek
KWKiedo Wienholts
Kiedo Wienholts
MKMatthijs Kox
Matthijs Kox
It is largely unknown whether the gut microbiome regulates immune responses in humans. We determined relationships between the microbiota composition and immunological phenotypes in 108 healthy volunteers, using 16S sequencing, an ex vivo monocyte challenge model, and an in vivo challenge model of systemic inflammation induced by lipopolysaccharide (LPS). Significant associations were observed between the microbiota composition and ex vivo monocytic cytokine responses induced by several stimuli, most notably IL-10 production induced by Pam3Cys, P. aeruginosa and C. albicans, although the explained variance was rather low (0.3 to 4.8%). Furthermore, a number of pairwise correlations between Blautia, Bacteroides and Prevotella genera and cytokine production induced by these stimuli were identified. LPS administration induced a profound transient in vivo inflammatory response. A second LPS challenge one week after the first resulted in a severely blunted response, reflecting endotoxin tolerance. However, no significant relationships between microbiota composition and in vivo parameters of inflammation or tolerance were found (explained variance ranging from 0.4 to 1.5%, ns). The gut microbiota composition explains a limited degree of variance in ex vivo monocytic cytokine responses to several pathogenic stimuli, but no relationships with the LPS-induced in vivo immune response or tolerance was observed.

25 June 2026 in Journal of Innate Immunity
Verified
Journal Article
Open access
SBSuzanne H. Bongers
Suzanne H. Bongers
BJBernard N. Jukema
Bernard N. Jukema
AJAron Jansen
Aron Jansen
DLDirk van Lier
Dirk van Lier
NWNicole Waalders
Nicole Waalders
NVNienke Vrisekoop
Nienke Vrisekoop
Introduction: During acute inflammation, such as experimental human endotoxemia, circulating neutrophil counts initially decrease followed by pronounced neutrophilia. Banded (CD16dim/CD62Lbright) and hypersegmented (CD16bright/CD62Ldim) neutrophils, which are absent in the blood during homeostasis, are rapidly mobilized. Banded and mature neutrophils are thought to be recruited from the bone marrow, while the origin of hypersegmented neutrophils remains disputed and underlying recruitment mechanisms remain to be established. Methods: Fifteen volunteers received an intravenous bolus of bacterial lipopolysaccharide followed by continuous infusion for 3 hours. Seven were randomly assigned to additional cytokine adsorption therapy, enabling analysis of neutrophil subsets across a broad range of circulating cytokine concentrations. Blood samples were obtained at baseline and 3 hours post-LPS bolus to assess neutrophil subset quantities, neutrophil surface activation markers, and plasma cytokine levels. Results: Circulating concentrations of pro-inflammatory cytokines (TNF, IL-6, IL-8, MIP-1α, and MCP-1) were negatively associated with circulating mature and banded neutrophil numbers, suggesting a role for these cytokines in their migration. The absence of a correlation between plasma cytokines with hypersegmented neutrophils indicates an alternative mobilization signal. In contrast to cell numbers, neutrophil activation markers positively correlated with concentrations of the various pro-inflammatory cytokines indicating involvement of cytokines in neutrophil activation. Conclusion: Circulating cytokines appear to be key drivers of mature and banded neutrophil migration whereas this complex signal does not influence the abundance of CD62Ldim cells in peripheral blood.